HeartBeam Study Shows Comparable Accuracy Between Portable 3D ECG System and Standard 12-Lead ECG
TL;DR
HeartBeam's compact 3D ECG device offers comparable accuracy to standard 12-lead systems, providing a competitive edge in portable cardiac monitoring technology.
HeartBeam's deep learning algorithms achieved 94.5% accuracy in detecting cardiac rhythms using a cable-free 3D device versus 95.5% with standard 12-lead ECGs.
HeartBeam's portable ECG technology enables advanced cardiac monitoring outside medical facilities, improving access to heart health management for patients worldwide.
HeartBeam's FDA-cleared 3D ECG device uses innovative deep learning to synthesize 12-lead data from a compact, cable-free system for cardiac rhythm detection.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam (NASDAQ: BEAT) announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter, and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups, with 94.5% for HeartBeam compared to 95.5% for standard 12-lead ECG.
The findings highlight the potential of HeartBeam's compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical. CEO Rob Eno emphasized that this technology could revolutionize cardiac care by enabling portable monitoring outside traditional medical facilities. The company plans to use these results to support future FDA submissions for its innovative cardiac monitoring platform.
HeartBeam's technology represents a significant advancement in cardiac care, creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, delivering actionable heart intelligence to physicians who can identify cardiac health trends and acute conditions outside of medical facilities.
The implications of this study are substantial for the healthcare industry and patients worldwide. The ability to achieve comparable accuracy with a portable device could democratize access to advanced cardiac monitoring, particularly in remote areas, home care settings, and during emergency situations where traditional 12-lead ECGs are not feasible. This technology has the potential to reduce healthcare costs by enabling earlier detection of cardiac issues and preventing unnecessary hospital visits.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review. The company holds over 20 issued patents related to technology enablement, positioning it as a leader in portable cardiac monitoring innovation. For more information about the company's technology and research, visit https://ibn.fm/BDiIa.
The study results validate HeartBeam's approach to transforming cardiac care through personalized insights and portable technology. As cardiovascular diseases remain a leading cause of death globally, innovations that make advanced cardiac monitoring more accessible could have profound impacts on public health outcomes. The ability to monitor cardiac health continuously outside clinical settings represents a paradigm shift in how healthcare providers approach preventive cardiology and chronic disease management.
Curated from NewMediaWire
